Aim: To review the currently available literature comparing the FEV 1 /FVC <LLN with a fixed value of FEV 1 /FVC <0.70 in diagnosing airflow obstruction in subjects aged >40 years. Methods: A structured MEDLINE, EMBASE and Cochrane search of English-language literature was conducted. Studies comparing prevalence rates according to the LLN and a fixed value were included. Attention was paid to the choice of the reference test or gold standard used. Results: Eighteen studies met the inclusion criteria. Sixteen studies compared the rates of subjects diagnosed with airflow obstruction by either definition of airflow obstruction without using a non-independent reference standard (level 4 studies). Using a fixed value of FEV 1 /FVC, an overall higher number of subjects were diagnosed with airflow obstruction that increased with age. Two studies included a follow-up phase comparing risks of either hospitalization or occurrence of respiratory symptoms and mortality (level 2b studies). Adjusted risks of hospitalization (HR 2.6) or mortality (HR 1.3) were significantly larger in subjects with an FEV 1 /FVC below 0.70 but above the LLN (in-between group) compared to subjects with normal lung function. Conclusion: The prevalence of spirometry-based COPD is greater when using the fixed value of FEV 1 /FVC in comparison to using the LLN. Based on one longitudinal study the in-between group appears to have a higher risk of hospitalization and mortality; therefore it seems that using the LLN of FEV 1 /FVC underestimates COPD. In absence of a gold standard of COPD longitudinal research will be necessary to determine which criterion is better and more clinically relevant. 
Summary
Aim: To review the currently available literature comparing the FEV 1 /FVC <LLN with a fixed value of FEV 1 /FVC <0.70 in diagnosing airflow obstruction in subjects aged >40 years. Methods: A structured MEDLINE, EMBASE and Cochrane search of English-language literature was conducted. Studies comparing prevalence rates according to the LLN and a fixed value were included. Attention was paid to the choice of the reference test or gold standard used. Results: Eighteen studies met the inclusion criteria. Sixteen studies compared the rates of subjects diagnosed with airflow obstruction by either definition of airflow obstruction without using a non-independent reference standard (level 4 studies). Using a fixed value of FEV 1 /FVC, an overall higher number of subjects were diagnosed with airflow obstruction that increased with age. Two studies included a follow-up phase comparing risks of either hospitalization or occurrence of respiratory symptoms and mortality (level 2b studies). Adjusted risks of hospitalization (HR 2.6) or mortality (HR 1.3) were significantly larger in subjects with an FEV 1 /FVC below 0.70 but above the LLN (in-between group) compared to subjects with normal lung function.
Conclusion:
The prevalence of spirometry-based COPD is greater when using the fixed value of FEV 1 /FVC in comparison to using the LLN. Based on one longitudinal study the in-between group appears to have a higher risk of hospitalization and mortality; therefore it seems that using the LLN of FEV 1 /FVC underestimates COPD. In absence of a gold standard of COPD longitudinal research will be necessary to determine which criterion is better and more clinically relevant. ª 2011 Elsevier Ltd. All rights reserved.
Introduction
Chronic obstructive pulmonary disease (COPD) will constitute the third leading cause of death by 2020 and it is currently the only chronic disease with increasing mortality rates. 1 COPD is preventable but irreversible and stabilizing the progression of the disease in an early phase appears to be the best therapy for decreasing morbidity and mortality and reducing health costs. 2 Consensus on the proper diagnostic criteria for COPD is essential.
It is widely accepted that the presence of airflow obstruction is key in diagnosing COPD. 2, 3 Airflow obstruction is present when the forced expiratory flow in 1 s (FEV 1 )/forced vital capacity (FVC) e ratio is reduced. 3 Another important sign of COPD is a decline in FEV 1 which is consequently used as a measure of the severity of airflow obstruction. 2 There is still a controversy regarding the appropriate cut-off values for FEV 1 /FVC. 4e6 In 2001, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) committee was the first to publish a consensus statement propagating the use of a fixed FEV 1 /FVC <0.70 value and fixed FEV 1 values to classify severity. 7 One of the objectives in introducing fixed values was to standardize and increase the awareness of diagnosing COPD, i.e. to simplify the diagnosis. However, more recently the GOLD committee recognized that using a fixed value of <0.70 may lead to potential overdiagnosis in the elderly. 2 In 2004, the ERS and the ATS issued a combined statement advocating the use of the lower limit of normal (LLN) instead of a fixed criterion. 8 The LLN is statistically defined by the lower fifth percentile of a reference population and can be calculated by subtracting 1.64 times the standard deviation from the mean, i.e. the expected value. The LLN is age-corrected. Using a fixed percentage instead of the LLN has several drawbacks as mentioned by Pellegrino et al. 4 One of the main arguments for discarding the fixed FEV 1 /FVC criterion is that it can lead to a COPD diagnosis in non-smoking elderly. 9 A large number of studies have compared the two COPD definitions in an attempt to decide which is more appropriate. This review aims to clarify the strengths and weaknesses of studies comparing the LLN with a fixed criterion. We focused on the study design and the choice of reference tests that were employed in these studies.
Methods

Search strategy
A structured search was conducted in Medline, EMBASE and the Cochrane library containing studies from January 1966 till June 2010. The search strings that were used contained synonyms and related terms for the "lower limit of normal". The Boolean operator "OR" was used to combine the search terms; the complete search string is noted in Table 1 . Moreover, all references from the bibliographies of the included articles were reviewed.
Article inclusion
After removing duplicates, F.M.H. and P.Z. independently screened all articles' titles and abstracts by applying inclusion and exclusion criteria (see flowchart, Fig. 1 ). Articles were included if (a) they pertained to studies comparing the LLN with a fixed criterion to diagnose spirometry-based COPD, (b) spirometry was performed in an adult population containing subjects !40 years and (c) they were written in English. If the abstract alone did not provide sufficient information to conclude that the article compared the LLN with a fixed value of FEV 1 /FVC, the fulltext was retrieved. Differences with respect to article inclusion were resolved by consensus between the two reviewers. Full-text versions of the included articles were retrieved if available and were read independently by both reviewers. 
Study appraisal
All included articles were appraised independently by F.M.H. and P.Z. on criteria concerning validity: (a) design, (b) study population, (c) presence or choice of a gold standard or reference test and (d) subject inclusion. Special attention was paid to the choice of the reference test/gold standard used. It was noted whether (1) only prevalence was reported according to either definition while no reference standard was used, (2) either one of the definitions was used as a reference test or (3) another kind of reference standard, like follow-up or a range of tests, was used. Levels of evidence were classified according to Oxford Centre for Evidence-based Medicine (CEBM) levels of evidence, see Table 2 .
10 Disagreement in study appraisal was resolved by consensus.
Data extraction
The reviewers independently extracted the following data: (a) number of subjects included, (b) percentage of males, (c) mean ages (standard deviation), (d) percentage of current smokers and (e) prevalence of COPD according to LLN and fixed FEV 1 /FVC criteria. If it was not provided, the percentage of smokers and prevalence rates were calculated by using the data provided in the text and tables of the article. Differences in the extracted data were resolved by consensus between the two reviewers.
Results
General
The search of the three databases yielded 1954 individual articles. After applying the inclusion criteria on the titles and abstracts, 30 articles were selected and the full-texts were retrieved. Two articles were not available as full text. 11, 12 Eleven articles were excluded after full-text screening because they did not meet the inclusion criteria. Screening of the references resulted in one additional publication. 13 In total, 18 articles were included as is mentioned in the flowchart search strategy (Fig. 1 ). In Table 3 , the authors, year of publication, number of included patients, percentage of males, study population, reference equation used for calculating predicted lung function and LLN, age groups, smoking status, and use of post-bronchodilator values were noted separately for each included study.
Six studies performed post-bronchodilator spirometry. The majority of the studies compared the fixed value of FEV 1 / FVC <0.70 against the LLN and thus used the LLN as their gold standard or reference test, see Table 4 . Only Mannino et al. used occurrence of COPD-based hospitalization and mortality during follow-up as a reference, while Vaz Fragoso used mortality and occurrence of respiratory symptoms as a reference. 20, 21 The remaining studies provided prevalence and discordance rates according to either definition, see Table 4 . The CEBM levels of evidence are provided in Table 4 .
Clinically based studies
Five studies were clinically based, i.e. including only referred or hospitalized subjects, and all had a crosssectional design. 13,14,22e24 All five studies included subjects over a wide age range, but unfortunately prevalence rates according to either definition were not consistently divided by age groups. Only the study by Schermer et al. provided separate rates for subjects aged 51e60; 61e70 and !71 years: it was the only clinically based study to include postbronchodilator spirometry values. 14 Prevalence rates according to a fixed FEV 1 /FVC of <0.70 were higher in these age groups than the prevalence rates according to the LLN, which ranged from 27.5% to 45% and from 20% to 25%, respectively. Discordant prevalence rates occurred in 4% up to 20% of the cases in this study.
Aggarwal et al. found an overall lower prevalence rate when applying FEV 1 /FVC <0.70 instead of the LLN, 23.6% and 28.2% respectively. 22 This stands in contrast to the other studies, but it should be noted that they included younger subjects. The studies by Margolis et al., Dejsomritrutai et al. and Roberts et al. found overall higher prevalence rates when FEV 1 /FVC <0.70 was used rather than the LLN (Table 4) . 13, 23, 24 Discordant results in these three studies occurred in 6%, 7.5% and 14.7% of the cases respectively. All five articles mentioned in their discussion the observation of growing prevalence differences between the two definitions based on increasing age, although exact numbers were not provided.
Population-based studies
Thirteen population-based studies were included.
15e21,25e30
Six studies used the NHANES III study population. 21,25e27,30,31 Three studies were performed in an Asian population. 15, 16, 28 Validating cohort studies with good reference standards or studies with clinician prediction rule within one centre 1c
Studies reporting high sensitivity/specificity 2a Systematic reviews with homogeneity of Level >2 studies 2b Systematic reviews with homogeneity or studies with clinical prediction rule from different clinical centres 3a Systematic reviews with homogeneity of Level >3 studies 3b
Non-consecutive studies or without consistently applied reference standards 4
Caseecontrol studies, poor or non-independent reference standard 5 Expert opinion 16e19, 28 In all other population-based studies only pre-bronchodilator values were used. Prevalence rates were higher in all studies after applying an FEV 1 /FVC <0.70 and the differences grew with increasing age (Table 4) . Prevalence rates according to FEV 1 /FVC increased more with age than did the prevalence rates according to LLN.
The study by Mannino et al. had a longitudinal design with mortality and COPD-related hospitalization as the primary outcomes. 20 4965 subjects (age >65 years) from the Cardiovascular Health Study (CHS) were included and were followed for nine years. The subjects were classified according to the FEV 1 /FVC <0.70 or LLN. 1134 subjects had an FEV 1 /FVC <0.70, but >LLN (in-between group). Subjects in the in-between group had a higher adjusted mortality risk (HR 1.3, CI95% 1.1e1.5) and an increased COPD-related hospitalization (HR 2.6, CI95% 2.0e3.0) in comparison to subjects with normal lung function. The outcome suggests that using the FEV 1 /FVC <0.70 identifies at-risk patients who would have been classified as normal according to LLN.
Vaz Fragoso et al. assessed data of 2480 subjects, aged 65e80, who were followed for 12 years and compared the risks of all-cause mortality and on respiratory symptoms between subjects with an FEV 1 /FVC <0.70 and <LLN (<5th percentile). 21 831 subjects had an FEV 1 /FVC <0.70, and 179 of these also had an FEV 1 /FVC <LLN. The adjusted hazard ratio of all-cause mortality in <LLN subjects was 2.01 (95%CI 1.60e2.54) and 1.24 (95%CI 1.04e1.47) for those who had <0.70 compared to those with normal lung function. The authors found no significant effects of either classification on the risk of respiratory symptoms being present. This outcome suggest that those with <0.70 have a lower risk of all-cause mortality compared to those with <LLN, yet the risk is still higher than those with normal lung function.
Comparing healthy never-smokers and current smokers
Vollmer et al., Hansen et al., Roche et al. and Swanney et al. also compared healthy never-smokers and found that COPD prevalence rates were higher when using a fixed value of FEV 1 /FVC <0.70. 18, 26, 29, 30 These differences increased especially with increasing age. The study by Vollmer et al. used post-bronchodilator values, but unfortunately only numbers for the non-smokers and not for the current smokers were reported. 18 
Discussion
This evidence-based review presents an overview of studies comparing the FEV 1 /FVC <LLN with FEV 1 /FVC <0.70 in diagnosing spirometry-based COPD. The majority of studies reviewed had a cross-sectional design and all concluded that using the <0.70 approach resulted in a greater prevalence of COPD, which was often interpreted as 'overdiagnosing COPD'. As mentioned by Vollmer et al., using the LLN as a threshold would probably miss subjects with mild airflow obstruction, but would correctly diagnose subjects with more profound and advanced airflow obstruction. 18 Taking this into consideration we have to ponder whether we can afford to miss those subjects who have only mild airflow obstruction since treatment options already may be present at an early stage.
Based on Table 4 it can be concluded that 13 out of 18 researchers made the a priori choice to adopt the LLN as their reference test. Unfortunately, this approach is flawed because the outcome of the comparison becomes predictable. Instead, the correct approach should be to select the diagnostic test that outperforms the other when both are tested against a gold standard. Unfortunately that golden standard test for COPD is lacking in all cases. The GOLD committee states that their cut-off points for COPD have not been clinically validated.
Ideally, the gold standard should be the perfect diagnostic test with a sensitivity and specificity of 100%. By adopting LLN as a reference or standard, one implicitly declares that this test is the gold standard and that any other test (e.g. the <0.70 approach) can deliver a maximal sensitivity/specificity of 100%, i.e. deliver equivalent results as the gold standard in terms of diagnosing or ruling out COPD. When the LLN is a "less than perfect" gold standard, and thus sometimes misdiagnoses or misses COPD as a result, one implicitly expects the new test to make the same mistakes in its attempt to deliver a maximal sensitivity/specificity of 100%. Even when the new test is "perfect", a comparison with a "less than perfect" test will deliver a sensitivity/specificity <100% and thus be inclined to regard the new test as being inferior. This is known as an 'imperfect gold standard bias' and is an important concept to bear in mind when interpreting the outcomes of such studies. 32 Reversing the choices by adopting the FEV 1 /FVC <0.70 as the reference would predictably lead to a sensitivity/specificity <100% of the LLN. The only valid conclusion one may draw when comparing diagnostic tests without a gold standard, is that they may produce different results. A conclusion regarding superiority or inferiority is not possible.
Some of the included studies did not report sensitivity and specificity values but provided agreement stated as kappa. Kappa is used to depict the extent of agreement between tests and its value ranges from 0 (no agreement) to 1 (perfect agreement). Again, in the absence of a gold standard, one should be cautious when interpreting kappa because in case of good agreement, one can only conclude that two tests are equivalent, not that either one is correct. As a consequence, due to the lack of a gold standard, the level of evidence according to the CEBM is 4.
A longitudinal study is probably the best option for obtaining a correct COPD diagnosis: time will tell whether or not a smoker's lung function declines. The decline in the lung function can be compared with the lung function of a never-smoker and the decline in lung function becomes the gold standard. Unfortunately, only two longitudinal studies were performed comparing the risks of hospitalization, the occurrence of respiratory symptoms and the mortality of subjects diagnosed with an FEV 1 /FVC <0.70 or <LLN. 20, 21 The study by Mannino et al. showed that subjects with an FEV 1 /FVC <0.70 but above the LLN had increased hospitalization and mortality rates, with hazard ratios of 2.6 and 1.3, respectively. At the same time, the study by Vaz Fragoso showed that subjects with an The disadvantage of cross-sectional studies is that they miss subjects with an accelerated decline in lung function, which may still have >0.70 or >LLN: it is inevitable that both measures will fall short in being the perfect diagnostic tools in cross-sectional studies. The point in time at which either of the two boundaries will be crossed partly depends on the initial height of lung function: subjects with a high initial lung function require more time to be labeled as COPD-subjects even though their lung function can decline as rapidly as in others. They remain 'healthy smokers' for a longer time. When rapidly declining subjects with an FEV 1 /FVC >0.70 are still labeled as 'non-diseased', a large number of COPD-subjects will be missed.
The pattern of lung function decline is therefore an issue in determining which of the two diagnostic tests is the least imperfect under cross-sectional conditions. In their wellknown study Fletcher and Peto found that FEV 1 -decline was initially small but became stronger as lung function decreased. 33 This phenomenon is referred to as the "horseracing effect". 34 By contrast, in the placebo-arms of the UPLIFT and TORCH studies, two randomized controlled studies (RCTs), lung function decline was more pronounced initially and slowed down as lung function lowered. 35, 36 Both patterns of decline are schematically depicted in Fig. 2 . If the 'Fletcher and Peto' pattern is valid, subjects will hover above both thresholds for longer periods of time and in cross-sectional studies neither the FEV 1 /FVC <0.70 or <LLN will be able to discriminate sufficiently between susceptible and non-susceptible smokers. On the other hand, when the 'UPLIFT and TORCH' pattern is valid, susceptible smokers will show rapid FEV 1 /FVC declines initially and therefore cross the <70% threshold in an early phase of their disease and the <LLN threshold in a later phase. The risk of missing susceptible smokers in a crosssectional study will thus be lower using the FEV 1 /FVC <0.70 value, whereas for the FEV 1 /FVC <LLN more time will pass, allowing greater lung function deterioration.
Another approach would be to distinguish those subjects with respiratory symptoms from those without. It has been shown that mild COPD subjects (GOLD stage I) without respiratory symptoms show no significantly faster FEV 1 -decline compared to those with normal lung function, i.e. FEV 1 /FVC >70%. 37 These results suggest that the presence of respiratory symptoms should be part of the definition of COPD. Our review focused on literature including older subjects, although one study conducted in younger subjects is worth mentioning. The study by De Marco et al. included subjects aged 20e44 years and compared FEV 1 -decline and hospitalization rates according to definition of airflow obstruction (<70% or <LLN). 38 The outcome was that subjects with respiratory symptoms had more significant FEV 1 -decline than subjects without respiratory complaints, regardless of which spirometric criteria were used.
An important and often cited argument for not using the FEV 1 /FVC <0.70 threshold is the observation of high prevalence rates of COPD in elderly healthy never-smokers. This argument is correct in our view, but at the same time is valued too high. COPD screening in subjects without prior Vaz Fragoso et al. tobacco addiction is less sensible. 39 No physician will/may label subjects without a prior smoking history and respiratory complaints as COPD based only on the outcomes of an FEV 1 /FVC value.
The availability of population-specific reference equations is essential for the utilization of the LLN worldwide. However, in many parts of the world, these populationspecific (post-bronchodilator) reference equations are not (yet) established. Instead, reference equations based on, for instance, the US-population like the NHANES III are used. This may result in biased outcomes when applying in non-US populations.
This present review has several limitations which need some attention. First, the majority of included studies only performed pre-bronchodilator spirometry. Differences in prevalence of airflow obstruction, as defined by FEV 1 /FVC <0.7 or <LLN, can be pre-/post-bronchodilator spirometry study dependent. However, at the moment it is not possible to estimate to what degree due to the lack of data. The few studies that performed both pre-and post-bronchodilator measurements did not report the pre-bronchodilator data. Second, studies with inconclusive results may not have been published and thus missed in our search. Third, two articles were not available in full text. 11, 12 Fourth, an English-language bias may be present because only the English-language literature was searched. Seeing as these limitations are similar to those encountered by the studies included in this review, we believe that this will not affect the validity of our conclusions.
Conclusion
A major shortcoming of the cited literature is that FEV 1 /FVC <0.70 and <LLN were not compared to a gold standard. However, defining such a standard is difficult. Nine out of the 18 included articles defined only the FEV 1 /FVC <LLN as their reference test and they influenced the outcome in favor of the FEV 1 /FVC <LLN. Therefore, based on the current available literature it cannot be determined whether it is preferable to use the LLN rather than to a fixed percentage of FEV 1 /FVC. Nevertheless, the outcome of the only included longitudinal study in which subjects with an FEV 1 /FVC <70% but >LLN are compared to those with normal lung function suggest that LLN may miss subjects at risk. Further longitudinal research will be necessary to determine which criterion is better and more clinically relevant. Until then, neither of the two approaches can be claimed to be superior over the other. 
